In 2015, estimates suggest there were over 9 million cases of pneumococcal disease globally, with 2.4 million cases in Africa alone. 318,000 deaths were attributed to the disease, representing 10% of all deaths in children under 5 years of age, primarily in sub-Saharan Africa.
Our study, "Determining whether mass campaigns with fractional dose PCV10 would accelerate herd protection against pneumococcal transmission in Sub-Saharan Africa", will explore the utility of mass-campaigns of PCV10 among children in Niger. We aim to evaluate whether a single 20% dose of PCV is non-inferior to a full dose in carriage reduction. Fractional dosing may reduce cost burden on countries with the highest burden through reduction of pneumococcal carriage.
To estimate vaccine efficacy against vaccine-type carriage 3 months after vaccination with a single fractional dose of PCV10 given to Nigerien children aged 1-9 years.
A cluster randomized trial with villages randomized to afractional (1/5) or full dose in children 1-9 years of age. We will assess effect on carriage 3 months after the campaign and compare with baseline.
The Project in numbers